Multiple sclerosis (relapsing-remitting) - alemtuzumab: evaluation report
1. Pre-Meeting Briefing
2. Submission from the technology manufacturer - Genzyme
3. NICE request to the manufacturer for clarification on their submission
4. Manufacturer clarification response
5. Consultee submission - Multiple Sclerosis Society
6. Consultee submission - Multiple Sclerosis Trust
7. Consultee submission - Association of British Neurologists
8. Consultee submission - Primary Care Neurology Society
9. Consultee submission - United Kingdom Clinical Pharmacy Association
10. Clinical expert personal perspective - COLES
11. Clinical expert personal perspective - COLHOUN
12. Clinical expert personal perspective - NICHOLAS
13. Patient expert personal perspective - BURCHMORE
14. Patient expert personal perspective - RIJKE
15. Evidence Review Group report prepared by Southampton Health Technology Assessment Centre
16. Errata to the ERG Report
17. SHTAC ERG Additional Analyses
18. Evidence Review Group report - factual accuracy check
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document.
Multiple sclerosis (relapsing-remitting) - alemtuzumab: evaluation report
05 December 2013 (10.58 Mb 36 sec) |
This page was last updated: 17 February 2014